Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzo[D]Thiazole SCHEMBL15385218 | 0.89 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL11359283 | 0.87 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL10009486 | 0.85 | MAPT (0.63) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL10432439 | 0.84 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL3401020 | 0.82 | MAPK1 (0.64) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL19357044 | 0.82 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL4345364 | 0.82 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL17038164 | 0.82 | PTPN1 (0.59) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL17038135 | 0.81 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT | |
| SCHEMBL2174930 | 0.81 | CYP2C9 (0.56) | ALDH1A1SMN1; SMN2RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059901-A | 1,3, 4-Oxadiazole compound and preparation method and application thereof | 成都大学 | 2026-05-19 | — | — | CN | claimed |
| US-10655015-B2 | Tire crumb-based bitumen polymer for producing a lower viscosity asphalt with improved tolerance to high temperatures | Argopro Group LLC (US) | 2020-05-19 | — | — | US | claimed |
| US-20200095424-A1 | TIRE CRUMB-BASED BITUMEN POLYMER FOR PRODUCING A LOWER VISCOSITY ASPHALT WITH IMPROVED TOLERANCE TO HIGH TEMPERATURES | Argopro Group LLC | 2020-03-26 | — | — | US | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| US-8586759-B2 | Methods and systems for synthesis of a D-aminoluciferin precursor and related compounds | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2013-11-19 | — | — | US | claimed |
| US-20110224442-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (LLNS) | 2011-09-15 | — | — | US | claimed |
| CN-122059901-A | 1,3, 4-Oxadiazole compound and preparation method and application thereof | 成都大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20250313564-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-10-09 | — | — | US | disclosed |
| EP-4547247-A2 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| EP-4471032-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-12-04 | — | — | EP | disclosed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2002100858-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5565445-A | ANTIBIOTICS, USEFUL AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS OR STAPHYLOCOCCUS EPIDERMIDIS AND METHICILLIN RESITANT COAGULASE NEGATIVE STAPHYLOCOCCI | MERCK & CO., INC. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5541176-A | ANTIBIOTICS, USEFUL AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS | MERCK & CO., INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5538964-A | ANTIBIOTICS FOR BACTERICIDES | MERCK & CO., INC. (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0395388-A2 | Image forming method | KONICA CORPORATION (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0315155-A2 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1989-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | ALDH1A1 335/4885SMN1; SMN2 1802/4885RAB9A 489/4885 |
| US-20110224442-A1 | METHODS AND SYSTEMS FOR SYNTHESIS OF A D-AMINOLUCIFERIN PRECURSOR AND RELATED COMPOUNDS | HCCS, HLCS, GLUL | ALDH1A1 2394/4885SMN1; SMN2 4724/4885RAB9A 4063/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | ALDH1A1 4148/4885SMN1; SMN2 2176/4885RAB9A 2492/4885 |
| US-20250313564-A1 | ACIDIC SALT OR CRYSTAL FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | NR5A1, HSD17B11, CYP17A1 | ALDH1A1 901/4885SMN1; SMN2 4839/4885RAB9A 1230/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | ALDH1A1 4757/4885SMN1; SMN2 4265/4885RAB9A 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.